Edgewise to Sell Muscle-Dystrophy Business to Servier for Up to $2.65 Billion
What’s happening
Edgewise Therapeutics agreed to sell its muscle-dystrophy business to Servier in a deal worth up to $2.65 billion.
The transaction gives Servier access to promising treatments being developed for rare muscle diseases while providing Edgewise with significant funding.
What’s changing / Business impact
The deal reflects continued interest in rare-disease medicines, one of the fastest-growing areas in biotechnology.
Large healthcare companies remain willing to spend billions for treatments that address serious conditions with limited existing options.
Why this matters
Although rare diseases affect smaller patient populations, successful treatments can be highly valuable because patients often have few alternatives.
Companies are increasingly investing in these specialized areas instead of focusing only on mass-market medicines.